Renin-angiotensin system activation in renal adipogenesis (Q43235382)

16 November 2017

Renin-angiotensin system activation in renal adipogenesis (English)

1 reference

16 November 2017

1 reference

Juliana Chung-ngor Chan

7

1 reference

16 November 2017

Yi Sui

1

1 reference

16 November 2017

Hai-Lu Zhao

2

1 reference

16 November 2017

Rong-Rong Fan

3

1 reference

16 November 2017

Jing Guan

4

1 reference

16 November 2017

Lan He

5

1 reference

16 November 2017

Heung Man Lee

6

1 reference

16 November 2017

Peter C Y Tong

8

1 reference

16 November 2017

25 November 2009

1 reference

American Journal of Physiology - Renal Physiology

16 November 2017

1 reference

16 November 2017

298

1 reference

16 November 2017

2

1 reference

16 November 2017

F391-400

1 reference

Long-term effects of fluoxetine on glycemic control in obese patients with non-insulin-dependent diabetes mellitus or glucose intolerance: influence on muscle glycogen synthase and insulin receptor kinase activity.

16 November 2017

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00445.2009

Role of mammalian target of rapamycin signaling in compensatory renal hypertrophy

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00445.2009

Temporal analysis of signaling pathways activated in a murine model of two-kidney, one-clip hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00445.2009

Effect of PPAR-alpha and -gamma agonist on the expression of visfatin, adiponectin, and TNF-alpha in visceral fat of OLETF rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00445.2009

Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00445.2009

Differentiation of preadipose cells: paracrine role of prostacyclin upon stimulation of adipose cells by angiotensin-II.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00445.2009

Adipose tissue distribution is different in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00445.2009

Pathological expression of renin and angiotensin II in the renal tubule after subtotal nephrectomy. Implications for the pathogenesis of tubulointerstitial fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00445.2009

Understanding adipocyte differentiation

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00445.2009

The roles of PPARs in adipocyte differentiation

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00445.2009

Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00445.2009

Molecular basis of partial lipodystrophy and prospects for therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00445.2009

Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Heart Outcomes Prevention Evaluation Study Investigators

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00445.2009

Why blockade of the renin-angiotensin system reduces the incidence of new-onset diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00445.2009

Mature adipocytes inhibit in vitro differentiation of human preadipocytes via angiotensin type 1 receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00445.2009

Angiotensin type 1 receptor antagonists induce human in-vitro adipogenesis through peroxisome proliferator-activated receptor-γ activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00445.2009

Peroxisome proliferator-activated receptor mediates cross-talk with thyroid hormone receptor by competition for retinoid X receptor. Possible role of a leucine zipper-like heptad repeat.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00445.2009

Mechanisms linking obesity to insulin resistance and type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00445.2009

New treatment strategies for patients with hypertension and insulin resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00445.2009

Treating the metabolic syndrome: telmisartan as a peroxisome proliferator-activated receptor-gamma activator

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00445.2009

PPAR gamma, 10 years later

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00445.2009

An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor gamma (PPAR gamma)

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00445.2009

Metabolic effects of troglitazone monotherapy in type 2 diabetes mellitus. A randomized, double-blind, placebo-controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00445.2009

Increased rate of gluconeogenesis in type II diabetes mellitus. A 13C nuclear magnetic resonance study

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00445.2009

The effects of rosiglitazone on insulin sensitivity, lipolysis, and hepatic and skeletal muscle triglyceride content in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00445.2009

Mechanisms by which angiotensin-converting enzyme inhibitors prevent diabetes and cardiovascular disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00445.2009

Development of diabetes is retarded by ACE inhibition in hypertensive patients--a subanalysis of the Captopril Prevention Project (CAPPP).

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00445.2009

Treating the metabolic syndrome using angiotensin receptor antagonists that selectively modulate peroxisome proliferator-activated receptor-gamma

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00445.2009

Reversal of nonalcoholic hepatic steatosis, hepatic insulin resistance, and hyperglycemia by moderate weight reduction in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00445.2009

Etiology of insulin resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00445.2009

AT-1 receptor blockade prevents proteinuria, renal failure, hyperlipidemia, and glomerulosclerosis in the Imai rat.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00445.2009

Angiotensin II as a trophic factor of white adipose tissue: stimulation of adipose cell formation

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00445.2009

Angiotensin type 1 receptor blockers induce peroxisome proliferator-activated receptor-gamma activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00445.2009

Angiotensin blockade prevents type 2 diabetes by formation of fat cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00445.2009

Effect of troglitazone on tumor necrosis factor alpha and transforming growth factor beta expression and action in human adipocyte precursor cells in primary culture

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00445.2009

Pancreatic islet beta-cell deficit and glucose intolerance in rats with uninephrectomy

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00445.2009

Stimulation of adipogenesis in fibroblasts by PPAR gamma 2, a lipid-activated transcription factor

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00445.2009

A comparison of outcomes with angiotensin-converting--enzyme inhibitors and diuretics for hypertension in the elderly.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00445.2009

Ramipril and the development of diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00445.2009

Deletion of the angiotensin type 2 receptor (AT2R) reduces adipose cell size and protects from diet-induced obesity and insulin resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00445.2009

Antihypertensive treatment in patients with type-2 diabetes mellitus: what guidance from recent controlled randomized trials?

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00445.2009

Fat redistribution and adipocyte transformation in uninephrectomized rats.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00445.2009

10.1152/AJPRENAL.00445.2009

21 January 2018

Identifiers

DOI

1 reference

release_v6er4tymfjht3iost52nc564pi

16 November 2017

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/v6er4tymfjht3iost52nc564pi

mapped directly with Wikidata item

24 November 2022

based on heuristic

1 reference